Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
147 hedge funds and large institutions have $202M invested in Synergy Pharmaceuticals, Inc Common Stock in 2018 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 39 increasing their positions, 44 reducing their positions, and 28 closing their positions.
7% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 28
2% less funds holding
Funds holding: 150 → 147 (-3)
11% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 44
31% less capital invested
Capital invested by funds: $292M → $202M (-$90.4M)
42% less call options, than puts
Call options by funds: $4.26M | Put options by funds: $7.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$9.67M |
| 2 |
Barclays
London,
United Kingdom
|
+$1.16M |
| 3 |
Millennium Management
New York
|
+$1.03M |
| 4 |
Morgan Stanley
New York
|
+$746K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$739K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$26.2M |
| 2 |
PC
Paulson & Co
New York
|
-$8.92M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$6.93M |
| 4 |
Citigroup
New York
|
-$3.45M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.11M |
SGYP Hedge Fund Activity: Q1 2018 in Review
147 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q1 2018, worth a combined $202M — down 31% from $292M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of SGYP and 26 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 39 added.
The largest buyer was Nantahala Capital Management, adding an estimated $9.67M. The largest seller was Susquehanna International Group, cutting an estimated $26.2M.
- 147 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q1 2018, down from 150 in Q4 2017.
- Funds reported $202M of Synergy Pharmaceuticals, Inc Common Stock stock for Q1 2018, down 31% quarter-over-quarter.
- 26 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q1 2018 and 28 closed out, a net change of -2 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q1 2018 was Nantahala Capital Management, an estimated $9.67M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q1 2018 was Susquehanna International Group, an estimated $26.2M sold.
Based on aggregated 13F filings for Q1 2018.